A randomized double blind placebo controlled clinical trial of buspirone for treating autism spectrum disorders

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201307303930N28

Enrollment

Registered

2014-04-04

Start date

2012-12-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pervasive developmental disorders. Childhood autism

Interventions

Intervention 1: risperidone (0.5 to 3 mg/day)+ Placebo. Intervention 2: risperidone (0.5 to 3 mg/day)+ Buspirone (10 to 20 mg/day).

Placebo

Treatment - Drugs

risperidone (0.5 to 3 mg/day)+ Placebo

risperidone (0.5 to 3 mg/day)+ Buspirone (10 to 20 mg/day)

Eligibility

Sex/Gender

All

Age

4 Years to 17 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: DSM-IV diagnosis of autism spectrum disorders; both genders; aged 4 to 17 years. Exclusion Criteria: a psychosis; and active substance abuse or dependency.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Abbrant Behavior Checklist- irritability subscale. Timepoint: Every 4 weeks. Method of measurement: Interveiw.	—

Secondary

Measure	Time frame
Adverse effects. Timepoint: every 4 weeks. Method of measurement: checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAnaheed Ayyobzadeh

Shiraz University of Medical Sciences

anaheed.shirazi@gmail.com+98 71 1627 3070

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026